Pub Date : 2026-02-07DOI: 10.1186/s12885-026-15696-x
Huseyin Ali Ozturk, Mevlut Koc, Ramazan Azim Okyay, Dilan Damla Ozturk, Erdinc Gulumsek, Mahmut Buyuksimsek, Mehmet Turker, Abdullah Eren Cetin, Fatih Necip Arici, Hilmi Erdem Sumbul
<p><strong>Aim: </strong>This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapagliflozin.</p><p><strong>Materials and methods: </strong>In this prospective observational study, a total of 60 newly diagnosed breast cancer patients with type 2 diabetes were enrolled. Thirty patients who had been treated with metformin and subsequently received dapagliflozin in addition to metformin during doxorubicin therapy constituted the dapagliflozin group. The non-dapagliflozin group consisted of 30 patients who, while continuing metformin, were initiated on another oral antidiabetic agent (excluding dapagliflozin) alongside doxorubicin therapy. N-terminal pro-B type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and left ventricular global longitudinal strain (LVGLS) were measured at baseline and at the 3rd month of treatment. Between-group baseline characteristics were compared using the independent samples t-test for continuous variables. Within-group changes from baseline to 3 months were analyzed with paired t-tests. Between-group comparisons of 3-month outcomes and changes (ΔLVEF, ΔLVGLS, ΔNT-proBNP) were also conducted using independent samples t-tests. To evaluate the independent effect of dapagliflozin on LVGLS, multivariable linear regression analysis was performed. Model fit was reported with adjusted R², F-statistics and 95% confidence intervals.</p><p><strong>Results: </strong>In the non-dapagliflozin group, LVEF and NT-proBNP levels showed no significant differences between baseline and post-treatment; however, LVGLS values significantly deteriorated. In contrast, the dapagliflozin group demonstrated a significant increase in LVEF (- 2.000 [95% CI - 2.392, - 1.608]) and LVGLS (+ 1.367 [95% CI + 1.159, + 1.574]), as well as a marked reduction in NT-proBNP levels (+ 64.933 [95% CI + 57.902, + 71.964]) after 3 months of treatment (p < 0.001). At the third month, the dapagliflozin group exhibited significantly better LVGLS (+ 2.133 [95% CI + 1.346, + 2.921]) and lower NT-proBNP levels (+ 57.000 [95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p < 0.001). Multivariable linear regression analysis confirmed that dapagliflozin use was independently associated with significant improvement in LVGLS at 3 months.</p><p><strong>Conclusion: </strong>In conclusion, dapagliflozin was associated with more favorable short-term surrogate changes in LVGLS and NT-proBNP during doxorubicin therapy. The favorable changes observed in LVEF, LVGLS, and NT-proBNP parameters suggest that dapagliflozin may be considered a potential cardioprotective agent and incorporated into preventive strategies against chemotherapy-related cardiotoxicity in diabetic patients. These hypothesis-generating findi
目的：本研究旨在通过超声心动图方法评估新诊断的乳腺癌合并2型糖尿病患者在二甲双胍的基础上同时接受达格列净治疗的阿霉素诱导的心脏毒性风险，并探讨达格列净的潜在心脏保护作用。材料与方法：本前瞻性观察研究共纳入60例新诊断的乳腺癌合并2型糖尿病患者。30例接受二甲双胍治疗的患者，在阿霉素治疗期间，在二甲双胍的基础上再接受达格列净治疗，构成达格列净组。非达格列净组包括30名患者，他们在继续使用二甲双胍的同时，在阿霉素治疗的同时开始使用另一种口服降糖药（不包括达格列净）。在基线和治疗第3个月测量n端前b型利钠肽（NT-proBNP）、左心室射血分数（LVEF）和左心室总纵向应变（LVGLS）。采用独立样本t检验对连续变量进行组间基线特征比较。用配对t检验分析从基线到3个月的组内变化。组间比较3个月的结果和变化（ΔLVEF， ΔLVGLS， ΔNT-proBNP）也采用独立样本t检验。为评价达格列净对LVGLS的独立影响，采用多变量线性回归分析。模型拟合报告采用调整后的R²、f统计量和95%置信区间。结果：在非达格列净组中，LVEF和NT-proBNP水平在基线和治疗后无显著差异；然而，LVGLS值明显恶化。相比而言，达格列净组在治疗3个月后LVEF （- 2.000 [95% CI - 2.392, - 1.608]）和LVGLS （+ 1.367 [95% CI + 1.159, + 1.574]）显著增加，NT-proBNP水平显著降低（+ 64.933 [95% CI + 57.902, + 71.964]） (p结论：达格列净与阿霉素治疗期间LVGLS和NT-proBNP的短期替代变化更有利相关。在LVEF、LVGLS和NT-proBNP参数中观察到的有利变化表明，达格列净可能被认为是一种潜在的心脏保护剂，可纳入糖尿病患者化疗相关心脏毒性的预防策略。这些产生假设的发现需要在更大规模的随机试验中得到证实，这些试验为临床终点提供了更长的随访时间。临床试验注册：不适用。
{"title":"Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study.","authors":"Huseyin Ali Ozturk, Mevlut Koc, Ramazan Azim Okyay, Dilan Damla Ozturk, Erdinc Gulumsek, Mahmut Buyuksimsek, Mehmet Turker, Abdullah Eren Cetin, Fatih Necip Arici, Hilmi Erdem Sumbul","doi":"10.1186/s12885-026-15696-x","DOIUrl":"https://doi.org/10.1186/s12885-026-15696-x","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapagliflozin.</p><p><strong>Materials and methods: </strong>In this prospective observational study, a total of 60 newly diagnosed breast cancer patients with type 2 diabetes were enrolled. Thirty patients who had been treated with metformin and subsequently received dapagliflozin in addition to metformin during doxorubicin therapy constituted the dapagliflozin group. The non-dapagliflozin group consisted of 30 patients who, while continuing metformin, were initiated on another oral antidiabetic agent (excluding dapagliflozin) alongside doxorubicin therapy. N-terminal pro-B type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and left ventricular global longitudinal strain (LVGLS) were measured at baseline and at the 3rd month of treatment. Between-group baseline characteristics were compared using the independent samples t-test for continuous variables. Within-group changes from baseline to 3 months were analyzed with paired t-tests. Between-group comparisons of 3-month outcomes and changes (ΔLVEF, ΔLVGLS, ΔNT-proBNP) were also conducted using independent samples t-tests. To evaluate the independent effect of dapagliflozin on LVGLS, multivariable linear regression analysis was performed. Model fit was reported with adjusted R², F-statistics and 95% confidence intervals.</p><p><strong>Results: </strong>In the non-dapagliflozin group, LVEF and NT-proBNP levels showed no significant differences between baseline and post-treatment; however, LVGLS values significantly deteriorated. In contrast, the dapagliflozin group demonstrated a significant increase in LVEF (- 2.000 [95% CI - 2.392, - 1.608]) and LVGLS (+ 1.367 [95% CI + 1.159, + 1.574]), as well as a marked reduction in NT-proBNP levels (+ 64.933 [95% CI + 57.902, + 71.964]) after 3 months of treatment (p < 0.001). At the third month, the dapagliflozin group exhibited significantly better LVGLS (+ 2.133 [95% CI + 1.346, + 2.921]) and lower NT-proBNP levels (+ 57.000 [95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p < 0.001). Multivariable linear regression analysis confirmed that dapagliflozin use was independently associated with significant improvement in LVGLS at 3 months.</p><p><strong>Conclusion: </strong>In conclusion, dapagliflozin was associated with more favorable short-term surrogate changes in LVGLS and NT-proBNP during doxorubicin therapy. The favorable changes observed in LVEF, LVGLS, and NT-proBNP parameters suggest that dapagliflozin may be considered a potential cardioprotective agent and incorporated into preventive strategies against chemotherapy-related cardiotoxicity in diabetic patients. These hypothesis-generating findi","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-07DOI: 10.1186/s12885-026-15707-x
Jibril Bashir Adem, Abebe Megerso Adilo, Haji Aman Deybasso, Muhammed Kabeto, Anas Ali Alhur, Tewodros Desalegn Nebi, Gadisa Dejene, Mengesha Akale Tekle, Jemal Reshad Tarie, Mifta Dellil Hamid, Melik Tiba, Abashamo Lencho
{"title":"Lived experience and attitudes of esophageal cancer patients toward stenting-based care at Asella referral hospital: a qualitative exploration from a resource-limited setting in South-Eastern Ethiopia.","authors":"Jibril Bashir Adem, Abebe Megerso Adilo, Haji Aman Deybasso, Muhammed Kabeto, Anas Ali Alhur, Tewodros Desalegn Nebi, Gadisa Dejene, Mengesha Akale Tekle, Jemal Reshad Tarie, Mifta Dellil Hamid, Melik Tiba, Abashamo Lencho","doi":"10.1186/s12885-026-15707-x","DOIUrl":"https://doi.org/10.1186/s12885-026-15707-x","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-07DOI: 10.1186/s12885-026-15632-z
Li Zhang, Fan Sun, Xiaorui Wang, Weipeng Zhao, Yongsheng Jia, Haotian Wang, Yuqi Han, Zhongsheng Tong
{"title":"Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.","authors":"Li Zhang, Fan Sun, Xiaorui Wang, Weipeng Zhao, Yongsheng Jia, Haotian Wang, Yuqi Han, Zhongsheng Tong","doi":"10.1186/s12885-026-15632-z","DOIUrl":"https://doi.org/10.1186/s12885-026-15632-z","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1186/s12885-026-15668-1
Ayse Selcen Oguz Erdogan, Yao Shu, Elske Gootjes, Femke Simmer, Iris D Nagtegaal
{"title":"Patients with tumor deposits benefit equally from adjuvant therapy compared to other stage III colon cancer groups: two retrospective population-based studies.","authors":"Ayse Selcen Oguz Erdogan, Yao Shu, Elske Gootjes, Femke Simmer, Iris D Nagtegaal","doi":"10.1186/s12885-026-15668-1","DOIUrl":"https://doi.org/10.1186/s12885-026-15668-1","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146123638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The extent to which anal and anorectal tumors are missed during endoscopic examinations has not been thoroughly investigated. This study investigated the clinical features of tumors that were missed during endoscopic examinations.
Aim: To investigate and analyze the endoscopic and clinical features of missed anal and anorectal tumors.
Methods: All patients diagnosed with anal and anorectal tumors between 2014 and 2024 at West China Hospital were included in this retrospective cohort analysis. Demographic data, tumor characteristics, endoscopic findings, and missed diagnosis records were extracted from electronic medical records and telephone follow-up. A descriptive and error-classification analysis was performed to identify the reasons for missed diagnoses during endoscopy.
Results: Descriptive and error-classification analysis among the 83 enrolled patients, 10 (7 with adenocarcinoma and 3 with squamous cell carcinoma) had undergone previous endoscopic examinations with negative diagnoses, resulting in a missed detection proportion of 12.0%. Six missed cases with 15 prior colonoscopies in which the lesions were overlooked had complete medical records. The mean number of endoscopic procedures performed prior to the definitive diagnosis was 2.5 (range: 1-5), with an average diagnostic delay of 43.4 months (range: 1-82). The causes of missed diagnoses included exposure errors (n = 8), judgment errors (n = 6), and biopsy errors (n = 1). The proportion of endoscopic rectal retroflexion to observe anus was 20% .
Conclusion: The missed diagnosis proportion of anal and anorectal tumors was high during endoscopic examination. Comprehensive endoscopic observation and enhanced recognition of the endoscopic features of anal tumors are essential.
{"title":"Missed anal and anorectal tumors during endoscopic examinations: a ten-year retrospective study.","authors":"Zhu-Jun Wu, Hui Gong, Ya-Xin Li, Yuan Li, Wei-Yi Wu, Lin-Jie Guo","doi":"10.1186/s12885-026-15671-6","DOIUrl":"https://doi.org/10.1186/s12885-026-15671-6","url":null,"abstract":"<p><strong>Background: </strong>The extent to which anal and anorectal tumors are missed during endoscopic examinations has not been thoroughly investigated. This study investigated the clinical features of tumors that were missed during endoscopic examinations.</p><p><strong>Aim: </strong>To investigate and analyze the endoscopic and clinical features of missed anal and anorectal tumors.</p><p><strong>Methods: </strong>All patients diagnosed with anal and anorectal tumors between 2014 and 2024 at West China Hospital were included in this retrospective cohort analysis. Demographic data, tumor characteristics, endoscopic findings, and missed diagnosis records were extracted from electronic medical records and telephone follow-up. A descriptive and error-classification analysis was performed to identify the reasons for missed diagnoses during endoscopy.</p><p><strong>Results: </strong>Descriptive and error-classification analysis among the 83 enrolled patients, 10 (7 with adenocarcinoma and 3 with squamous cell carcinoma) had undergone previous endoscopic examinations with negative diagnoses, resulting in a missed detection proportion of 12.0%. Six missed cases with 15 prior colonoscopies in which the lesions were overlooked had complete medical records. The mean number of endoscopic procedures performed prior to the definitive diagnosis was 2.5 (range: 1-5), with an average diagnostic delay of 43.4 months (range: 1-82). The causes of missed diagnoses included exposure errors (n = 8), judgment errors (n = 6), and biopsy errors (n = 1). The proportion of endoscopic rectal retroflexion to observe anus was 20% .</p><p><strong>Conclusion: </strong>The missed diagnosis proportion of anal and anorectal tumors was high during endoscopic examination. Comprehensive endoscopic observation and enhanced recognition of the endoscopic features of anal tumors are essential.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1186/s12885-026-15665-4
Guangfeng Zhang, Feng Gao, Lei Fan, Wenbin Guo, Jianshe Zhao
{"title":"The diagnostic value of enhanced CT radiomics and deep learning in differentiating pediatric peripheral neuroblastoma from ganglioneuroblastoma.","authors":"Guangfeng Zhang, Feng Gao, Lei Fan, Wenbin Guo, Jianshe Zhao","doi":"10.1186/s12885-026-15665-4","DOIUrl":"https://doi.org/10.1186/s12885-026-15665-4","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1186/s12885-026-15634-x
Banu Iskender, Mehmet Sarihan, Bengi Su Rumeysa Barlak, Gurler Akpinar, Murat Kasap
{"title":"Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation.","authors":"Banu Iskender, Mehmet Sarihan, Bengi Su Rumeysa Barlak, Gurler Akpinar, Murat Kasap","doi":"10.1186/s12885-026-15634-x","DOIUrl":"https://doi.org/10.1186/s12885-026-15634-x","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146123669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1186/s12885-026-15657-4
Silas Ojuka, Alex Duhimbaze, Samuel Michael Nono, Moses Nangosya, John Isiiko, Tadele Mekuriya Yadesa
{"title":"Factors associated with occurrence of drug therapy problems among patients with neoplasms of s-sectional studydigestive organs at Uganda Cancer Institute, Mbarara: a cros.","authors":"Silas Ojuka, Alex Duhimbaze, Samuel Michael Nono, Moses Nangosya, John Isiiko, Tadele Mekuriya Yadesa","doi":"10.1186/s12885-026-15657-4","DOIUrl":"https://doi.org/10.1186/s12885-026-15657-4","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1186/s12885-026-15681-4
Li Xiaozhe, Chen Meilan, Liu Junru, Gu Jingli, Huang Beihui, Kuang Lifen, Li Juan
{"title":"Correction to: Evolving treatments and outcomes in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a real-world study in China.","authors":"Li Xiaozhe, Chen Meilan, Liu Junru, Gu Jingli, Huang Beihui, Kuang Lifen, Li Juan","doi":"10.1186/s12885-026-15681-4","DOIUrl":"10.1186/s12885-026-15681-4","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"26 1","pages":"189"},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12879368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：